Plain-English translation of NCT06292780 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new experimental medication called for adults with AL amyloidosis—a serious condition where abnormal proteins build up and damage organs like the heart and kidneys. The study will first test the medication in a small group of people to find the safest dose, then give it to a larger group to see if it actually helps treat the disease. Researchers want to understand how well this medication works, what side effects it may cause, and what dose works best.
Many people with AL amyloidosis find that their condition comes back or stops responding to current treatments, leaving them with limited options. This trial exists to see whether this new medication might offer hope for patients who have exhausted other therapies and need a new way to fight their disease.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. In Phase 1, a small group receives the medication at different doses to test safety and find the best dose. In Phase 2, a larger group receives the medication (at either a lower or higher dose) to further evaluate safety and measure how well it works against the disease. You will likely have regular clinic visits for blood tests, heart and kidney function checks, and monitoring for side effects over several months.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States